Wednesday, October 12, 2011

Chantix Suicide Most Critical Side Effect of Quit Smoking Drug


In 2008 The FDA announced a public health advisory about abnormal behavior, agitation, Chantix depression, suicidal ideation, and actual suicidal behavior with Pfizer’s anti-smoking drug. The FDA provided updated numbers - 491 cases of suicidal thinking or behavior, including 420 in the US and of those, there were 39 suicides, including 34 in the US. Many of the cases were reported for patients without any prior history of psychiatric illness. Government scientists are conducting further investigating into the drug and, specifically, the reports of Chantix suicide and suicidal ideation. Chantix, approved in 2006, works by blocking nicotine receptors to the brain. Chantix is the first such nicotine receptor partial agonist approved by the FDA. It was heralded as an alternative to other smoking cessation drugs and nicotine replacement therapy.

Tuesday, October 11, 2011

Chantix Heart Attack Evidence Mounting


Many users of the popular smoking cessation drug are familiar with the adverse Chantix side effects that have been linked to the drug, including psychological conditions and cardiovascular problems.  These risks  include suicidal thoughts, suicide, increased rage or aggression, depression, and mood swings as well as Chantix heart attack, vascular disease, angina pectoris, and coronary revascularization. These problems, particularly the ones related to heart problems, can also manifest in smokers because of the smoking itself, making filing lawsuits regarding Chantix heart problems a little more tricky than they might otherwise be.

Wednesday, October 5, 2011

Chantix Multidistrict Litigation Inching Forward


Although Chantix litigation has been consolidated in multidistrict litigation, as presided over by District Judge Inge P. Johnson, since October of 2009, many plaintiffs and other interested parties are unaware of the progress it has been making since it was consolidated. At the time of the consolidation, which was requested in July of 2009, there were only 34 Chantix lawsuits involved. Now, there are more than 1,200 that have been filed in courts across the country and are being consolidated in multidistrict litigation, which will combine pretrial processes in similar cases in order to expedite the legal process.
            Most Chantix cases involved in multidistrict litigation are related to Chantix suicide and suicide attempts, which is one of the more common psychological side effects of the popular smoking cessation aid. However, there are a multitude of other Chantix side effects listed as

Tuesday, October 4, 2011

Chantix Lawsuit Settlements Gauged by Bellwether Trials


Although Chantix lawsuits are still coming in from across the country, thousands of lawsuits that have already been combined in Chantix multidistrict litigation are preparing for trials in the coming years. These cases, largely dealing with Chantix-related psychological problems like anxiety, depression, and Chantix suicide have been consolidated in a process that will speed litigation and help plaintiffs reach a settlement more quickly, as pretrial processes in similar cases are combined.
            Chantix psychological problems are a highly-publicized phenomenon which seems to develop mostly in patients with a personal or family history of psychological disorders or behavioral and emotional problems. These same people were deliberately left out of Chantix clinical trials by drugmaker Pfizer, despite the fact that statistically, people with psychological problems are much more likely to be smokers than people without these conditions. Suicidal thoughts and suicide attempts are not uncommon Chantix side effects, and some

Friday, September 30, 2011

Chantix Lawsuits Making Progress: Update


Chantix, the popular smoking cessation drug that has plagued some users with serious side effects, is about to be at the centre of a series of trials set to take place in the Northern District of Alabama. Over 1,200 Chantix lawsuits have been consolidated in multidistrict litigation that has not yet begun, but both parties will begin preparing evidence from the initial discovery pool this fall, and trials will commence from there. In multidistrict litigation, pretrial processes are completed as one, and then cases may be sent back to the courts from which they originated.
Plaintiffs are filing suit on behalf of themselves or a family member who has experienced one of many severe Chantix side effects, including suicide attempts and suicide ideation, episodes of rage, heart problems, aggressive behavior, and heart attacks. The cases center around the assertion that Pfizer did not adequately warn patients of the potential for many of these serious side effects. In addition, there is concern over the way Chantix was tested. Subjects with a history of mental illness were not included in Chantix clinical trials, despite the fact that statistically people with a history of mental illness or mental problems are much more likely to smoke. In addition, people with such a history are the ones most likely to be affected by Chantix psychological side effects.

Tuesday, September 27, 2011

Chantix Suicide Numbers Increase as More Information Discovered


The smoking cessation drug Chantix has been linked to a number of serious psychological side effects. These possible Chantix side effects include aggression, rage, mood swings, depression, and suicidal thoughts not characteristic of a patient’s thoughts and behavior before taking the medication. Despite this, Chantix continues to be one of the most popular smoking cessation products on the market today. Pfizer, the manufacturer of Chantix, is coming under fire both for its clinical trial accuracy and the fact that they appear to have been hiding information about Chantix from the food and Drug Administration.
Initially, there were 122 reports of Chantix suicide reported by Pfizer. It has come to light, however, that about 150 cases of Chantix-related suicide or suicide of those taking Chantix were known, but not reported to the Food and Drug Administration. Combined, almost 300 cases of Chantix suicide have been reported. This means that the danger associated with Chantix-related suicide is more than twice what was originally thought – and spells trouble for Pfizer, especially as they are now faced with victims filing many a Chantix lawsuit.
Chantix heart attack is another side effect that is especially worrisome to patients and legal experts. Heart attacks are one of the most deadly conditions today, and Chantix seems to put patients at greater risk of suffering one. Is it possible that Chantix heart attacks, like Chantix suicides, have been seriously

Thursday, September 8, 2011

Heart Attacks And Suicide Lead To Chantix Lawsuits

In January of this year, David Collins killed himself with a shotgun just three months after he began taking Chantix (varenicline) a smoking cessation drug made by Pfizer. Linda Collins who is David Collins widow has filed a lawsuit in Indianapolis against Pfizer over Chantix side effects and its possible failure to provide warnings to users. Mr. Collins had no prior history of mental illness, but before his suicide Mr. Collins exhibited aggression and strange behavior. Lawsuits allege that Pfizer was negligent because it manufactured and marketed an unsafe drug. The FDA approved Chantix in May 2006. By the end of 2006, Chantix was listed among a group of 35 drugs that received more than 100 serious injury reports per calendar quarter. By mid-2007, Chantix ranked third among all drugs in reported problems.

In the last quarter of 2007, Chantix users reported 988 adverse events, more than any other marketed drug. Lawsuits assert that Pfizer should be held strictly liable for manufacturing and marketing this unsafe drug. Drug manufacturers must perform clinical tests before drugs are marketed. The manufacturer must ensure that the drugs are safe and effective. Chantix lawsuits claim that Pfizer did not perform enough clinical trials before it marketed Chantix. Pfizer failed to conduct Chantix studies using individuals with psychiatric histories or current psychiatric symptoms. Lawsuits allege that if sufficient pre-market testing was performed, Pfizer may have determined that Chantix depression and suicide had a link.

Last month, the FDA warned that, in addition to the risk of increased aggressive behavior, some users of the stop-smoking drug Chantix may face an increased risk of heart attacks and other heart problems. Chantix has already been linked to an increased risk of a number of potential health problems. The FDA issued the warning after reviewing data from a clinical trial involving 700 smokers, half of whom were given Chantix instead of a placebo to help them quit smoking. Researchers found that 2% of the users of Chantix suffered a heart attack within a year, twice as many as smokers given a placebo, among the other heart problems.